Key Takeaways
- • Quantinuum is targeting a $12.7 billion valuation in its US IPO, seeking to raise $1.05 billion by marketing approximately 21 million shares at $45–$50 per share on Nasdaq.
- • The Honeywell-backed quantum computing company posted a net loss of $136.6 million on revenue of $5.2 million for Q1 2026, compared with a $30.5 million loss on $19.1 million in revenue a year prior, indicating significant cash burn despite growing market interest.
- • Quantinuum's roadmap targets the delivery of its "Apollo system"—a commercial-scale, fully fault-tolerant quantum computer—before the end of the decade, positioning the company as a frontrunner in quantum computing commercialization.
- • The company counts Amgen and Mitsui & Co. among its early users and collaborators, with platforms under development for chemistry, machine learning, cybersecurity, finance, and drug discovery applications.
- • The IPO capitalizes on surging institutional investor appetite for quantum computing, reflecting broader enthusiasm for the sector's potential to address complex computational problems in AI, cryptography, and scientific research.
Summary
Quantinuum Inc., a quantum computing developer backed by Honeywell International, has filed for a US initial public offering targeting a $12.7 billion valuation. According to its SEC filing, the company plans to offer approximately 21 million shares priced between $45 and $50 per share, generating gross proceeds of $1.05 billion. At the upper end of the pricing range, Quantinuum would achieve a market capitalization of $12.7 billion at the time of listing.
The Broomfield, Colorado-based company is positioning itself as a leader in quantum computing commercialization at a critical inflection point for the sector. CEO Rajeeb Hazra stated in the investor letter that Quantinuum is "executing a roadmap to the first commercial-scale, fully fault-tolerant quantum computer before the end of this decade," with the company's Apollo system serving as the target delivery vehicle for this milestone. The company's platform applications span chemistry, machine learning, cybersecurity, finance, and drug discovery—sectors where quantum computing's exponential computational advantages could deliver transformative value.
The company's financial profile reflects the capital intensity of quantum research and development. For the three months ended March 31, 2026, Quantinuum reported a net loss of $136.6 million on revenue of $5.2 million. This represents a significant deterioration from the prior-year period, which showed a $30.5 million loss on $19.1 million in revenue. The widening loss despite lower revenue signals elevated R&D and operational spending as the company scales infrastructure toward its fault-tolerant quantum systems roadmap.
Quantinuum's customer base and strategic partnerships underscore growing enterprise confidence in quantum computing's near-term viability. The company counts pharmaceutical leader Amgen and diversified conglomerate Mitsui & Co. among its early users and collaborators. The IPO timing aligns with accelerating venture capital inflows into quantum computing—the sector attracted $4.9 billion in private VC funding in 2025, representing 192% year-over-year growth. This market momentum reflects institutional recognition that quantum computers will be critical infrastructure for addressing cryptographic vulnerabilities, optimizing complex systems, and advancing AI research.
The Broomfield, Colorado-based company is positioning itself as a leader in quantum computing commercialization at a critical inflection point for the sector. CEO Rajeeb Hazra stated in the investor letter that Quantinuum is "executing a roadmap to the first commercial-scale, fully fault-tolerant quantum computer before the end of this decade," with the company's Apollo system serving as the target delivery vehicle for this milestone. The company's platform applications span chemistry, machine learning, cybersecurity, finance, and drug discovery—sectors where quantum computing's exponential computational advantages could deliver transformative value.
The company's financial profile reflects the capital intensity of quantum research and development. For the three months ended March 31, 2026, Quantinuum reported a net loss of $136.6 million on revenue of $5.2 million. This represents a significant deterioration from the prior-year period, which showed a $30.5 million loss on $19.1 million in revenue. The widening loss despite lower revenue signals elevated R&D and operational spending as the company scales infrastructure toward its fault-tolerant quantum systems roadmap.
Quantinuum's customer base and strategic partnerships underscore growing enterprise confidence in quantum computing's near-term viability. The company counts pharmaceutical leader Amgen and diversified conglomerate Mitsui & Co. among its early users and collaborators. The IPO timing aligns with accelerating venture capital inflows into quantum computing—the sector attracted $4.9 billion in private VC funding in 2025, representing 192% year-over-year growth. This market momentum reflects institutional recognition that quantum computers will be critical infrastructure for addressing cryptographic vulnerabilities, optimizing complex systems, and advancing AI research.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.